FDA granted priority review designation of Roche’s Actemra

News Hour:

The U.S. Food and Drug Administration (FDA) has granted priority review designation of Roche’s rheumatoid arthritis medication Actemra for giant cell arteritis (GCA), the Swiss drugmaker said on Tuesday.

“We will continue to work closely with the FDA to bring this investigational medicine to people with GCA as quickly as possible,” Sandra Horning, Roche’s chief medical officer and head of global product development, said in a statement, reports Reuters.

Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries, most often in the head but also in the aorta and its branches.

 
Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Waste management an essential public service in the fight to beat COVID-19
Human chain on International Women's Day by SERAC-Bangladesh
HIV and AIDS: Facts and Forewarning in the context of Bangladesh
Bangladesh will work with UK to fight corona, reiterates PM
Nabila-Manoj in Aryan’s new drama ‘Mon Mondire’
Juventus players agree to take pay reduction in 90-million-euro cost cut

Advertisement

News of the Month

January 2017
S M T W T F S
« Dec   Feb »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: